Tarsus Pharmaceuticals, Inc. (TARS)
73.50
+1.74
(+2.42%)
USD |
NASDAQ |
Aug 31, 11:49
Tarsus Pharmaceuticals Cash from Investing (Quarterly) : 37.88M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 37.88M |
| March 31, 2026 | -58.56M |
| December 31, 2025 | 49.27M |
| September 30, 2025 | -4.743M |
| June 30, 2025 | -51.70M |
| March 31, 2025 | -34.94M |
| December 31, 2024 | -59.57M |
| September 30, 2024 | 3.128M |
| June 30, 2024 | -40.52M |
| March 31, 2024 | -102.22M |
| December 31, 2023 | 17.85M |
| September 30, 2023 | 47.37M |
| June 30, 2023 | 64.09M |
| March 31, 2023 | 11.29M |
| Date | Value |
|---|---|
| December 31, 2022 | -87.22M |
| September 30, 2022 | -57.13M |
| June 30, 2022 | -0.122M |
| March 31, 2022 | -0.161M |
| December 31, 2021 | -0.274M |
| September 30, 2021 | -0.121M |
| June 30, 2021 | -0.016M |
| March 31, 2021 | -0.175M |
| December 31, 2020 | 0.05M |
| September 30, 2020 | -0.135M |
| June 30, 2020 | -0.335M |
| March 31, 2020 | -0.036M |
| December 31, 2019 | -0.024M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Veradermics, Inc. | -277.29M |
| ANI Pharmaceuticals, Inc. | -3.054M |
| Corcept Therapeutics, Inc. | -29.24M |
| Veru, Inc. | 1.802M |
| Johnson & Johnson | -1.11B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 61.22M |
| Cash from Financing (Quarterly) | 3.302M |
| Free Cash Flow | 56.00M |
| Free Cash Flow Per Share (Quarterly) | 1.317 |
| Free Cash Flow to Equity (Quarterly) | 57.17M |
| Free Cash Flow to Firm (Quarterly) | 59.68M |
| Free Cash Flow Yield | 1.77% |